Prescription drug · BLA
Taltz (ixekizumab) NDC 0002-8900
Ixekizumab 20 mg/.25mL · Injection, Solution · Subcutaneous · Eli Lilly and Company
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0002-8900-11 | 00002890011 | 1 SYRINGE in 1 CARTON (0002-8900-11) / .25 mL in 1 SYRINGE (0002-8900-01)Marketed from Feb 2, 2024 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Taltz
- Generic name (nonproprietary)
- ixekizumab
- Active ingredients
- Ixekizumab — 20 mg/.25mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Labeler
- Eli Lilly and Company
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 125521
- Marketing start
- Listing expires
- Other FDA classes
- Interleukin-17A Antagonists (Mechanism)
- Identifiers
- Product ID 0002-8900_1c6425de-1f8c-4385-bfb9-6e01db55275fSPL ID 1c6425de-1f8c-4385-bfb9-6e01db55275fSPL set ID ac96658a-d7dc-4c7c-8928-2adcdf4318b2RxCUI 1745103, 1745108, 1745112, 1745114, 2674931, 2674932, 2674933, 2674934UNII BTY153760O
- Pharmacologic class
- Interleukin-17A Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N400002890011followed by a unit qualifier and the quantityPackage 00002-8900-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults with active psoriatic arthritis. ( 1.2 ) adults with active ankylosing spondylitis. ( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. ( 1.4 ) 1.1 Plaque Psoriasis TALTZ ® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis TALTZ is indicated for the treatment of adult patients wi…
Excerpt only. Read the full label for complete information.
Other NDCs under BLA 125521
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Taltzixekizumab | Ixekizumab 40 mg/.5mL | Injection, SolutionSubcutaneous | Eli Lilly and Company | 0002-8905 |
| Taltzixekizumab | Ixekizumab 80 mg/mL | Injection, SolutionSubcutaneous | Eli Lilly and Company | 0002-7724 |
| Taltzixekizumab | Ixekizumab 80 mg/mL | Injection, SolutionSubcutaneous | Eli Lilly and Company | 0002-1445 |